Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

161. Cohort study: Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes

Cohort study: Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes Article

2015 Evidence-Based Nursing

162. Causes and risk factors: Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia

Causes and risk factors: Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia Article Text

2015 Evidence-Based Mental Health

163. Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia

Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia Article Text Psychological interventions Sustained

2015 Evidence-Based Mental Health

164. Rexulti (brexpiprazole) - To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder

Rexulti (brexpiprazole) - To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder REXULTI (brexpiprazole) Tablets U.S. Department of Health and Human Services Search FDA Submit search REXULTI (brexpiprazole) Tablets ENTRESTO Company: Otsuka Pharmaceutical Company, Ltd. Application No.: 205422Orig1s000 and 205422Orig2s000 Approval Date: July 10, 2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

2015 FDA - Drug Approval Package

165. Helping people with schizophrenia to quit smoking

Helping people with schizophrenia to quit smoking Helping people with schizophrenia to quit smoking | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Helping people with schizophrenia to quit smoking Article Text Evidence-based case conference Helping people with schizophrenia to quit smoking Free Toshi A Furukawa Statistics from Altmetric.com Clinical case Patient A 38-year-old man. Present illness The patient developed schizophrenia in his mid

Full Text available with Trip Pro

2015 Evidence-Based Mental Health

166. Metformin to reduce weight gain and metabolic disturbance in schizophrenia

Metformin to reduce weight gain and metabolic disturbance in schizophrenia Metformin to reduce weight gain and metabolic disturbance in schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin to reduce weight gain and metabolic disturbance in schizophrenia Article Text Pharmacological interventions Metformin to reduce weight gain and metabolic disturbance in schizophrenia Guy Faulkner , Mark Duncan Statistics from

2015 Evidence-Based Mental Health

167. Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia

Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia Article Text Causes and risk factors Environmental

2015 Evidence-Based Mental Health

168. Acupuncture for schizophrenia. (PubMed)

Acupuncture for schizophrenia. Acupuncture, with many categories such as traditional acupuncture, electroacupuncture, laser acupuncture, and acupoint injection, has been shown to be relatively safe with few adverse effects. It is accessible and inexpensive, at least in China, and is likely to be widely used there for psychotic symptoms.To review the effects of acupuncture, alone or in combination treatments compared with placebo (or no treatment) or any other treatments for people (...) with schizophrenia or related psychoses.We searched Cochrane Schizophrenia Group's Trials Register (February 2012), which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO and clinical trials registries. We also inspected references of identified studies and contacted relevant authors for additional information.We included all relevant randomised controlled trials involving people with schizophrenia-like illnesses, comparing acupuncture added to standard dose antipsychotics

Full Text available with Trip Pro

2014 Cochrane

169. Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. (PubMed)

Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between the various first-generation antipsychotics, however, low-potency first-generation antipsychotic drugs are sometimes perceived as less efficacious than high-potency first-generation compounds by clinicians, and they also seem to differ in their side effects.To review (...) the effects of high-potency, first-generation perphenazine compared with low-potency, first-generation antipsychotic drugs for people with schizophrenia.We searched the Cochrane Schizophrenia Group Trials Register (October 2010).We included all randomised controlled trials (RCTs) comparing perphenazine with first-generation, low-potency antipsychotic drugs for people with schizophrenia or schizophrenia-like psychoses.We extracted data independently. For dichotomous data we calculated risk ratios (RR

2014 Cochrane

170. Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. (PubMed)

Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between antipsychotic drugs, however, low-potency antipsychotic drugs are sometimes perceived as less efficacious than high-potency compounds by clinicians, and they also seem to differ in their side effects.To review the effects in clinical response of flupenthixol and low-potency (...) antipsychotics for people with schizophrenia.We searched the Cochrane Schizophrenia Group Trials Register (July 2010).Randomised controlled trials that compared flupenthixol with first-generation low-potency antipsychotic drugs for people with schizophrenia or schizophrenia-like psychosis.We extracted data independently. For continuous data, we calculated mean differences (MD) based on a random-effects model.The review currently includes one randomised trial from mainland China with 153 participants

2014 Cochrane

171. Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. (PubMed)

Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between any other antipsychotic compounds, however, low-potency antipsychotic drugs are often perceived as less efficacious than high-potency compounds by clinicians, and they also seem to differ in their side effects. This review examined the effects of the high-potency (...) antipsychotic fluphenazine compared to those of low-potency antipsychotics.To review the effects of fluphenazine and low-potency antipsychotics for people with schizophrenia.We searched the Cochrane Schizophrenia Group Trials Register (November 2010).We included all randomised controlled trials (RCTs) comparing fluphenazine with first-generation low-potency antipsychotic drugs for people with schizophrenia or schizophrenia-like psychosis.We extracted data independently. For dichotomous data we calculated

Full Text available with Trip Pro

2014 Cochrane

172. Aripiprazole monohydrate (Abilify Maintena) - for the maintenance treatment of schizophrenia in adult patients stabilised with oral arip

Aripiprazole monohydrate (Abilify Maintena) - for the maintenance treatment of schizophrenia in adult patients stabilised with oral arip Final Appraisal Recommendation Advice No: 2214 – July 2014 Aripiprazole (Abilify Maintena ® ) 400 mg powder and solvent for prolonged release suspension for injection Submission by Otsuka Pharmaceuticals (UK) Ltd and Lundbeck Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (...) release suspension for injection is recommended as an option for use within NHS Wales for the maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

2014 All Wales Medicines Strategy Group

173. Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia

Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia HAS - Medical, Economic and Public Health Assessment Division 1/16 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 19 February 2014 RISPERDAL 1 mg, scored film-coated tablet B/60 (CIP: 34009 338 948 7 0) RISPERDAL 2 mg, scored film-coated tablet B/60 (CIP (...) concerned National Health Insurance (French Social Security Code L.162-17) Hospital use (French Public Health Code L.5123 2) Indications concerned "RISPERDAL/RISPERDALORO is indicated for the treatment of schizophrenia." "RISPERDAL/RISPERDALORO is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorders." "RISPERDAL/RISPERDALORO is indicated for the short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from

2014 Haute Autorite de sante

174. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia

Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Lurasidone (Latuda - Sunovion Pharmaceuticals (...) Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that lurasidone be listed for the management of the manifestations of schizophrenia if the following clinical criteria are met: 1. Patient has a contraindication to less expensive antipsychotic agents, or 2. Patient has failed a trial of less expensive antipsychotics because of intolerance

2014 Health Technology Assessment (HTA) Database.

175. Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia

Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation CADTH. Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Clinical Report. 2014 Authors' conclusions The main reason for the original CDEC recommendation of "Do Not List" was a lack of sufficient evidence to establish the comparative efficacy of lurasidone against other AAPs. In this updated review, no additional RCTs meeting the inclusion

2014 Health Technology Assessment (HTA) Database.

176. Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia

Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation CADTH. Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Pharmacoeconomic Report. 2014 Authors' conclusions At the submitted price of XXXXXX, lurasidone (XXXXXX per year) is less expensive than aripiprazole ($1,509 to $1,746 per year) and ziprasidone ($1,448 per year). Therefore, lurasidone would

2014 Health Technology Assessment (HTA) Database.

177. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. (PubMed)

Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between antipsychotic compounds, however, low-potency antipsychotic drugs are often clinically perceived as less efficacious than high-potency compounds, and they also seem to differ in their side-effects.To review the effects in clinical response of haloperidol and low-potency (...) antipsychotics for people with schizophrenia.We searched the Cochrane Schizophrenia Group Trials Register (July 2010).We included all randomised trials comparing haloperidol with first-generation low-potency antipsychotic drugs for people with schizophrenia or schizophrenia-like psychosis.We extracted data independently. For dichotomous data, we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. For continuous data, we

2014 Cochrane

178. Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. (PubMed)

Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between any other antipsychotic compounds, however, low-potency antipsychotic drugs are often perceived as less efficacious than high-potency compounds by clinicians, and they also seem to differ in their side-effects.To review the effects in response to treatment (...) of trifluoperazine and low-potency antipsychotics for people with schizophrenia.We searched the Cochrane Schizophrenia Group's Trials Register (November 2010).We included all randomised trials comparing trifluoperazine with first-generation low-potency antipsychotic drugs for people with schizophrenia or schizophrenia-like psychosis.We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects

Full Text available with Trip Pro

2014 Cochrane

179. Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. (PubMed)

Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. Long-acting depot injections of drugs such as flupenthixol decanoate are extensively used as a means of long-term maintenance treatment for schizophrenia.To evaluate the effects of flupenthixol decanoate in comparison with placebo, oral antipsychotics and other depot neuroleptic preparations for people with schizophrenia and other severe mental illnesses, in terms of clinical, social and economic outcomes.We (...) identified relevant trials by searching the Cochrane Schizophrenia Group Trials Register in March 2009 and then for this update version, a search was run in April 2013. The register is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO. References of all identified studies were inspected for further trials. We contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information.All randomised controlled trials that focused on people

2014 Cochrane

180. Horticultural therapy for schizophrenia. (PubMed)

Horticultural therapy for schizophrenia. Horticultural therapy is defined as the process of utilising fruits, vegetables, flowers and plants facilitated by a trained therapist or healthcare provider, to achieve specific treatment goals or to simply improve a person's well-being. It can be used for therapy or rehabilitation programs for cognitive, physical, social, emotional, and recreational benefits, thus improving the person's body, mind and spirit. Between 5% to 15% of people (...) with schizophrenia continue to experience symptoms in spite of medication, and may also develop undesirable adverse effects, horticultural therapy may be of value for these people.To evaluate the effects of horticultural therapy for people with schizophrenia or schizophrenia-like illnesses compared with standard care or other additional psychosocial interventions.We searched the Cochrane Schizophrenia Group Trials Register (Janurary 2013) and supplemented this by contacting relevant study authors, and manually

Full Text available with Trip Pro

2014 Cochrane